Griseofulvin

Antimycotic. Out of commerce in Germany for economic reasons! Can be imported as a single import according to §73 AMG)

22 h

Fungistatic effect, inhibition of mitosis of dermatophytes. Incorporation into newly formed keratin of hair roots, nail matrix and epidermis (latency period 30 days).

Systemic in severe dermatophyte infections. Approved antimycotic against trichophyton and microsporum species in children. Topically used for the treatment of superficial dermatomycoses and for supportive therapy of Tinea unguium.

• Cream: Apply 1-3 times/day to the affected skin areas.
• Systemic: 0.5-1 g/day for 3 months p.o., children < 14 years: 10-20 mg/kg bw/day (equivalent to 1-3.5 tablets of a preparation containing 125 mg griseofulvin); treatment duration: 4-8 weeks. Take unchewed with a fatty meal with liquid.

5% as cream.

• Topical: Paragroup allergy.
• Systemic: nervousness, gastrointestinal problems, headache, fatigue, xerostomia, blood count changes (leukopenia, neutropenia, monocytosis).

Notice! Under griseofulvin, check the blood count twice in the first month of treatment, later every 2-3 months. Due to potential teratogenicity, effective contraception should be used, whereby the effect of oral contraceptives is reduced. Men should not conceive children during treatment and up to 6 months afterwards! Hepatotoxicity!

See Table 1.

Liver and kidney damage (e.g. acute hepatic porphyria), pregnancy, lactation, collagenosis, acute hepatic porphyria.

Notice! Caution in case of known penicillin allergy (griseofulvin is produced by Penicillium species).

Likuden, Gricin cream, Griseo 125

1. Mayser P et al (2020) S1 guideline Tinea capitis. JDDG 18: 161-181

2. Seebacher C et al (2006) Tinea capitis. J Dtsch Dermatol Ges 4: 1085-1091

Significant interactions of griseofulvin